18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy

Esther Mena, Maria Liza Lindenberg, Barış Türkbey, Joanna H. Shih, Stephanie A. Harmon, Ilhan Lim, Frank I. Lin, Stephen Adler, Philip Eclarinal, Yolanda McKinney, Deborah E. Citrin, William L. Dahut, Bradford J. Wood, Venkatesh Krishnasamy, Richard Chang, Elliot Levy, Maria J. Merino, Peter A. Pinto, Janet F. Eary, Peter L. ChoykeJournal of Nuclear Medicine 2019 · DOI

Abstract

Objective: To investigate the lesion detection rate of <sup>18</sup>F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)-targeted PET agent, in patients with biochemically relapsed prostate cancer after primary local therapy. Methods: This was a prospective institutional review board-approved study of 90 patients with documented biochemical recurrence (median PSA, 2.5 ng/mL) and negative results on conventional imaging. Patients underwent whole-body <sup>18</sup>F-DCFPyL PET/CT. Results were correlated with PSA, PSA kinetics, and original primary tumor grade. Results: 77.8% of patients showed positive PSMA PET results. Detection rates were 47.6%, 50%, 88.9%, and 94% for PSA levels of >0.2 to <0.5, 0.5 to <1.0, 1 to <2.0, and ≥2.0 ng/mL, respectively. In postsurgical patients, PSA kinetics correlated with PET results. Positive predictive value was 93.3% by histopathologic validation. Conclusion: <sup>18</sup>F-DCFPyL PET/CT offers high detection rates in biochemically recurrent prostate cancer patients, even at low PSA levels (<0.5 ng/mL), which could substantially impact clinical management.

Introduction

For many prostate cancer patients, primary treatment—such as radical prostatectomy or radiation—is followed by a period of biochemical recurrence (BCR), characterized by rising prostate-specific antigen (PSA) levels without visible tumors on conventional CT or bone scans. This clinical "ghost hunt" makes it difficult to localize the recurrence and plan effective salvage therapy. While first-generation PSMA tracers have improved detection, they face logistical challenges. This study evaluates <sup>18</sup>F-DCFPyL, a second-generation fluorine-18 labeled tracer that offers superior image resolution and easier distribution from centralized cyclotrons.

Methods

A prospective study was conducted with 90 patients experiencing BCR and negative conventional imaging. The cohort included patients who had undergone radical prostatectomy (n=38), radiation (n=27), or both (n=25). Patients on androgen deprivation therapy were excluded. Whole-body <sup>18</sup>F-DCFPyL PET/CT scans were performed 2 hours post-injection. Findings were correlated with absolute PSA levels and PSA kinetics, specifically doubling time and velocity. Validation was performed via histopathology or clinical follow-up in 40% of positive cases.

Key Results

The overall detection rate was 77.8%, with 287 lesions identified across 70 patients. The majority of these lesions were located in lymph nodes (208), followed by the prostate bed (37) and distant sites (42).

Crucially, the detection rate remained high even at very low PSA levels. For patients with PSA levels between 0.2 and 0.5 ng/mL—the window where salvage therapy is most effective—the tracer identified lesions in 47.6% of cases. Detection rates increased significantly as PSA levels rose, reaching 94% for PSA ≥ 2.0 ng/mL.

Detection rates of 18F-DCFPyL PET/CT stratified by PSA level (A), PSA doubling time (B), and PSA velocity (C).

In postsurgical patients, PSA doubling time and velocity were strong predictors of a positive scan. However, this correlation was not observed in postradiation patients, suggesting that the remaining treated prostate tissue may confound PSA kinetics as a trigger for imaging.

Discussion and Clinical Impact

The high positive predictive value (93.3% by histology, 96.2% with clinical follow-up) underscores the reliability of <sup>18</sup>F-DCFPyL. Beyond simple detection, the study provided insights into the anatomical spread of recurrent disease. At PSA levels below 1.0 ng/mL, recurrence is typically confined to the pelvis (prostate bed or pelvic lymph nodes). As PSA levels increase, the proportion of extrapelvic disease, including retroperitoneal lymph nodes and bone metastases, rises sharply.

Anatomical distribution of 18F-DCFPyL PET-positive lesions by PSA level.

The use of <sup>18</sup>F as a radioisotope offers significant logistical advantages over <sup>68</sup>Ga. With a half-life of 110 minutes, <sup>18</sup>F-DCFPyL can be produced at central manufacturing sites and shipped to regional hospitals, facilitating broader clinical adoption of high-sensitivity PSMA PET imaging.

Conclusion

<sup>18</sup>F-DCFPyL PET/CT is a highly promising tool for localizing recurrent prostate cancer, particularly in patients with low PSA levels where conventional imaging fails. By identifying disease in nearly half of patients with PSA < 0.5 ng/mL, this technology could fundamentally shift the management of biochemical recurrence toward more precise and effective salvage interventions. Future research will focus on whether this early detection translates into improved metastasis-free survival.

Summary updated

Abstract

Our objective was to investigate the lesion detection rate of <sup>18</sup>F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)-targeted PET agent, in patients with biochemically relapsed prostate cancer after primary local therapy. <b>Methods:</b> This was a prospective institutional review board-approved study of 90 patients with documented biochemical recurrence (median prostate-specific antigen [PSA], 2.5 ng/mL; range, 0.21-35.5 ng/mL) and negative results on conventional imaging after primary local therapies, including radical prostatectomy (<i>n</i> = 38), radiation (<i>n</i> = 27), or a combination of the two (<i>n</i> = 25). Patients on androgen deprivation therapy were excluded. Patients underwent whole-body <sup>18</sup>F-DCFPyL PET/CT (299.9 ± 15.5 MBq) at 2 h after injection. The PSMA PET lesion detection rate was correlated with PSA, PSA kinetics, and original primary tumor grade. <b>Results:</b> Seventy patients (77.8%) showed positive PSMA PET results, with a total of 287 lesions identified: 37 prostate bed foci, 208 lesions in lymph nodes, and 42 in distant sites in bones or organs, Eleven patients had negative results, and 9 patients showed indeterminate lesions, which were considered negative in this study. The detection rates were 47.6% (<i>n</i> = 10/21), 50% (<i>n</i> = 5/10), 88.9% (<i>n</i> = 8/9), and 94% (<i>n</i> = 47/50) for PSA levels of >0.2 to <0.5, 0.5 to <1.0, 1 to <2.0, and ≥2.0 ng/mL, respectively. In postsurgical patients, PSA, PSA doubling time, and PSA velocity correlated with PET results, but the same was not true for postradiation patients. These parameters also correlated with the extent of disease on PET (intrapelvic vs. extrapelvic). There was no significant difference in the rate of positive scans between patients with higher-grade and lower-grade primary tumors (Gleason score of ≥4 + 3 vs. <3 + 4). Tumor recurrence was histology-confirmed in 40% (28/70) of patients. On a per-patient basis, positive predictive value was 93.3% (95% confidence interval, 77.6%-99.2%) by histopathologic validation and 96.2% (95% confidence interval, 86.3%-99.7%) by the combination of histology and imaging/clinical follow-up. <b>Conclusion:</b><sup>18</sup>F-DCFPyL PET/CT imaging offers high detection rates in biochemically recurrent prostate cancer patients and is positive in about 50% of patients with a PSA level of less than 0.5 ng/mL, which could substantially impact clinical management. In postsurgical patients, <sup>18</sup>F-DCFPyL PET/CT correlates with PSA, PSA doubling time, and PSA velocity, suggesting it may have prognostic value. <sup>18</sup>F-DCFPyL PET/CT is highly promising for localizing sites of recurrent prostate cancer.
BibTeX
@article{mena2019sup,
  author = {Esther Mena and Maria Liza Lindenberg and Barış Türkbey and Joanna H. Shih and Stephanie A. Harmon and Ilhan Lim and Frank I. Lin and Stephen Adler and Philip Eclarinal and Yolanda McKinney and Deborah E. Citrin and William L. Dahut and Bradford J. Wood and Venkatesh Krishnasamy and Richard Chang and Elliot Levy and Maria J. Merino and Peter A. Pinto and Janet F. Eary and Peter L. Choyke},
  title = {{<sup>18</sup>F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy}},
  journal = {Journal of Nuclear Medicine},
  year = {2019},
  doi = {10.2967/jnumed.119.234799},
}
Figure